Human FGFR4/β-Klotho Reporter Assay System

• Ready to Use Upon Receipt
• Includes All Needed Components
• Contains Transfected Reporter Cells

Eliminates Cell Licensing Fees

• Clear, Reproducible Results
• Consistent Results Lot to Lot

This is an all-inclusive cell-based luciferase reporter assay kit targeting the Human Fibroblast Growth Factor Receptor 4 and β-Klotho (FGFR4/β-Klotho). INDIGO’s FGFR4/β-Klotho reporter assay utilizes proprietary mammalian cells that have been engineered to provide constitutive expression of the Human Fibroblast Growth Factor Receptor 4 and β-Klotho. In addition to FGFR4/β-Klotho Reporter Cells, this kit provides two optimized media for use during cell culture and in diluting the user’s test samples, a reference agonist, Luciferase Detection Reagent, and a cell culture-ready assay plate. The principal application of this assay is in the screening of test samples to quantify any functional activity, either agonist or antagonist, that they may exert against human FGFR4/β-Klotho. This kit provides researchers with clear, reproducible results, exceptional cell viability post-thaw, and consistent results lot to lot.

The family of Fibroblast Growth Factors (FGFs) comprise approximately 23 members that are related by core sequence and structure conservation, with the majority of FGFs being secreted signaling proteins. Secreted FGFs are predominantly autocrine and paracrine factors, with only three members evolved to function as endocrine factors1. FGFs bind and activate FGF Receptors (FGFRs) which, themselves, are members of the family of high-affinity tyrosine kinase receptors.

Aberrant FGF-19 signaling mediated by its receptor, FGFR4 and co-receptor β-Klotho, is known to be a driver of hepatocellular carcinoma (HCC). Consequently, FGF-19 and FGFR4/β-Klotho command considerable interest as therapeutic targets in drug development and drug safety screening.